Page 1

FOR IMMEDIATE RELEASE Electromed , Inc. Announces Fiscal 2022 First Quarter Financial Results -- Record quarterly revenue of $ 10.0 million , 25.0 % growth vs. prior year driven by strong growth in home care and institutional markets -- - New Prague , Minnesota – November 9 , 2021 – Electromed , Inc. ( “ Electromed ” or the “ Company ” ) ( NYSE American : ELMD ) , a leader in innovative airway clearance technologies , today announced financial results for the three months ended September 30 , 2021 ( " Q1 FY 2022 " ) . Q1 FY 2022 Highlights • Net revenue increased 25.0 % to $ 10.0 million , from $ 8.0 million for the three months ended September 30 , 2020 ( " Q1 FY 2021 " ) , driven by 24.4 % home care revenue growth and 61.5 % institutional revenue growth . • Gross profit percentage increased to 77.0 % of net revenue , from 76.8 % of net revenue in Q1 FY 2021. The increase in gross profit percentage in Q1 FY 2022 was primarily due to favorable revenue mix , partially offset by increased raw material and shipping costs . • Operating income totaled $ 538,000 , compared to $ 663,000 in Q1 FY 2021. The decrease in operating income was due to increased strategic investments in SG & A and costs related to shareholder activism , partially offset by stronger revenue performance . • Net income equaled $ 439,000 , or $ 0.05 per diluted share , compared to $ 535,000 , or $ 0.06 per diluted share , in Q1 FY 2021 . • Cash totaled $ 11.0 million as of September 30 , 2021 . Kathleen Skarvan , President and Chief Executive Officer of Electromed , commented , “ In the first quarter of fiscal 2022 , we achieved record quarterly net revenue of $ 10.0 million , with exceptional year - over - year growth in both our home care and institutional businesses . Our results were driven by strong execution across the Company and from the benefits of our key strategic growth investments , primarily in commercial team expansion and direct - to - consumer and digital marketing . In our home care business , our sales team continued to execute admirably through a hybrid virtual and face - to - face selling approach , maintaining a high level of productivity despite somewhat dampened clinician access after the onset of the COVID - 19 Delta variant . On the institutional side of our business , we were pleased to see hospitals increasingly resume utilization of high frequency chest wall oscillation protocols during the quarter , after reducing utilization early in the COVID - 19 pandemic . " Ms. Skarvan continued , “ I believe that the strategic investments we are making in commercial expansion and digital marketing , product development , clinical research studies , and system infrastructure improvements position Electromed for enhanced long- term revenue growth , increased operating leverage , and durable shareholder value creation . In the remainder of fiscal 2022 , we will focus on completing the final phases of development of our next generation airway clearance device , enrolling additional patients in our multi - center prospective clinical outcomes study , prudently building our sales and marketing team with an eye on maintaining high productivity , and diligently executing our direct - to - patient marketing program to increase awareness of Smart VestⓇ as an effective device for the treatment of bronchiectasis . "